Physician profile
John Walker
NPI 1861631947
$2,396.33
in general payments reported to CMS, 2019-2025
34 companies · $479 in 2025
The $479 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $511 · 2020: $261 · 2021: $465 · 2022: $489 · 2023: $80.56 · 2024: $112 · 2025: $479.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $671.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $671.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $365.11 | 2021-2025 | Vraylar |
| Stryker Corporation | $170.79 | 2025 | Clottriever Bold Catheter, Flowtriever |
| Amarin Pharma, INC. | $156.90 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $152.06 | 2019-2022 | |
| Glaxosmithkline, LLC. | $135.95 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $126.36 | 2019-2022 | |
| Lilly USA, LLC | $101.11 | 2019-2024 | Mounjaro |
| Novo Nordisk INC | $97.42 | 2019-2023 | Ozempic, Rybelsus |
| Astellas Pharma US INC | $93.88 | 2019-2021 | |
| Supernus Pharmaceuticals, INC. | $91.44 | 2019-2020 | |
| Amgen INC. | $80.92 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $80.85 | 2020-2022 | |
| Astrazeneca Pharmaceuticals Lp | $78.41 | 2019-2024 | |
| Pfizer INC. | $72.83 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $56.94 | 2019-2024 | Vaxneuvance, Vaxelis, Vaqta |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $53.21 | 2019-2022 | |
| Alkermes, INC. | $51.13 | 2019-2023 | Vivitrol |
| Vanda Pharmaceuticals INC. | $48.19 | 2025 | Hetlioz, Fanapt |
| Novartis Pharmaceuticals Corporation | $38.40 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $35.58 | 2024-2025 | Rexulti, Abilify Maintena |
| Esperion Therapeutics, INC. | $34.24 | 2021 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $33.38 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $31.03 | 2020-2022 | |
| Allergan, INC. | $26.34 | 2019-2020 | |
| Eisai INC. | $25.73 | 2019-2020 | |
| Owp Pharmaceuticals, INC. | $22.54 | 2025 | Subvenite |
| Phathom Pharmaceuticals, INC. | $22.41 | 2025 | Voquezna |
| Daiichi Sankyo INC. | $19.14 | 2021 | |
| Dynavax Technologies Corporation | $18.49 | 2022 | |
| Sanofi Pasteur INC. | $17.11 | 2019 | |
| Avanir Pharmaceuticals, INC. | $16.40 | 2019 | |
| Shield Therapeutics INC | $15.04 | 2022 | |
| Abbott Laboratories | $14.88 | 2021 | |
| Sk Life Science, INC. | $12.12 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Walker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.